Literature DB >> 16278744

Voriconazole: the newest triazole antifungal agent.

Nickie D Greer1.   

Abstract

Entities:  

Year:  2003        PMID： 16278744      PMCID： PMC1201014          DOI： 10.1080/08998280.2003.11927910

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN： 0899-8280


× No keyword cloud information.
  25 in total

1.  Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia.

Authors:  S Schwartz; D Milatovic; E Thiel
Journal:  Br J Haematol       Date:  1997-06       Impact factor: 6.998

2.  In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.

Authors:  A Espinel-Ingroff
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

3.  In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi.

Authors:  E M Johnson; A Szekely; D W Warnock
Journal:  J Antimicrob Chemother       Date:  1998-12       Impact factor: 5.790

4.  International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program.

Authors:  M A Pfaller; D J Diekema; R N Jones; H S Sader; A C Fluit; R J Hollis; S A Messer
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

5.  A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients.

Authors:  R Ally; D Schürmann; W Kreisel; G Carosi; K Aguirrebengoa; B Dupont; M Hodges; P Troke; A J Romero
Journal:  Clin Infect Dis       Date:  2001-09-26       Impact factor: 9.079

6.  Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.

Authors:  T J Walsh; R W Finberg; C Arndt; J Hiemenz; C Schwartz; D Bodensteiner; P Pappas; N Seibel; R N Greenberg; S Dummer; M Schuster; J S Holcenberg
Journal:  N Engl J Med       Date:  1999-03-11       Impact factor: 91.245

Review 7.  Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.

Authors:  J A Goldstein
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

8.  Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study.

Authors:  Hillard M Lazarus; Jeffrey L Blumer; Saul Yanovich; Haran Schlamm; Alain Romero
Journal:  J Clin Pharmacol       Date:  2002-04       Impact factor: 3.126

9.  A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients.

Authors:  H G Prentice; I M Hann; R Herbrecht; M Aoun; S Kvaloy; D Catovsky; C R Pinkerton; S A Schey; F Jacobs; A Oakhill; R F Stevens; P J Darbyshire; B E Gibson
Journal:  Br J Haematol       Date:  1997-09       Impact factor: 6.998

10.  Organism-dependent fungicidal activities of azoles.

Authors:  E K Manavathu; J L Cutright; P H Chandrasekar
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191
View more
  9 in total

1.  Haemorrhagic cystitis following the administration of voriconazole in the treatment of central nervous system aspergillosis: a case report.

Authors:  Zhaohao Zeng; Hong Luo; Kunyu Huang; Lianfang Xue; Hui Liu; Xiaoting Li; Lu Wang; Haimei Cen; Wei Bi; Yu Zhang
Journal:  J Int Med Res       Date:  2020-12       Impact factor: 1.671

2.  Combined effect of furanone fluconazole and amphotericin B against biofilms formed from Cryptococcus neoformans.

Authors:  Kirishnamoorthy Meenakumari; Giridharan Bupesh
Journal:  Bioinformation       Date:  2021-05-31

3.  Intractable Nausea in a Heart Transplant Patient.

Authors:  Julian Yet Kwong Horman; Michael Schultz
Journal:  Cureus       Date:  2022-07-13

4.  Improvements in Sepsis-associated Mortality in Hospitalized Patients with Cancer versus Those without Cancer. A 12-Year Analysis Using Clinical Data.

Authors:  Alissa J Cooper; Steven P Keller; Christina Chan; Brett E Glotzbecker; Michael Klompas; Rebecca M Baron; Chanu Rhee
Journal:  Ann Am Thorac Soc       Date:  2020-04

Review 5.  Ecology of aspergillosis: insights into the pathogenic potency of Aspergillus fumigatus and some other Aspergillus species.

Authors:  Caroline Paulussen; John E Hallsworth; Sergio Álvarez-Pérez; William C Nierman; Philip G Hamill; David Blain; Hans Rediers; Bart Lievens
Journal:  Microb Biotechnol       Date:  2016-06-07       Impact factor: 5.813

6.  Expanding the chemical space of 3(5)-functionalized 1,2,4-triazoles.

Authors:  Dmytro M Khomenko; Roman O Doroshchuk; Yulia M Ohorodnik; Hanna V Ivanova; Borys V Zakharchenko; Ilona V Raspertova; Oleksandr V Vaschenko; Alexey V Dobrydnev; Oleksandr O Grygorenko; Rostyslav D Lampeka
Journal:  Chem Heterocycl Compd (N Y)       Date:  2022-03-23       Impact factor: 1.490

Review 7.  Assessment of greenness for the determination of voriconazole in reported analytical methods.

Authors:  Hemanth Kumar Chanduluru; Abimanyu Sugumaran
Journal:  RSC Adv       Date:  2022-02-28       Impact factor: 3.361

Review 8.  Oesophageal candidiasis in elderly patients: risk factors, prevention and management.

Authors:  Namal Weerasuriya; Jeremy Snape
Journal:  Drugs Aging       Date:  2008       Impact factor: 4.271

9.  Towards the Elucidation of the Pharmacokinetics of Voriconazole: A Quantitative Characterization of Its Metabolism.

Authors:  Josefine Schulz; Antonia Thomas; Ayatallah Saleh; Gerd Mikus; Charlotte Kloft; Robin Michelet
Journal:  Pharmaceutics       Date:  2022-02-22       Impact factor: 6.321
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.